Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

short hairpin RNA-IL-6 gene silencing anti-CD19 CAR T cells

A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing a short hairpin RNA (shRNA) against the pro-inflammatory cytokine interleukin-6 (IL-6), and linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunostimulating and antineoplastic activities. Upon administration, short hairpin RNA-IL-6 gene silencing anti-CD19 CAR T cells target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. IL-6 gene silencing reduces IL-6 gene expression and release. This may inhibit IL-6-mediated toxicity due to high IL-6 levels and may prevent severe cytokine release syndrome (CRS) and CAR-T-related encephalopathy (CRES).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD19-CAR Ts with shRNA-IL-6 gene silencing
short hairpin RNA-IL-6-modified anti-CD19 CAR Ts
shRNA-IL-6-modified anti-CD19 CAR Ts
shRNA)-IL-6 gene silencing anti-CD19 CAR T cells
ssCART-19 cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search